Evidence map›Paper›PMID 37227782›Full record

ArticleJCI insight2023

Orai1 calcium channel inhibition prevents progression of chronic pancreatitis.

Viktória Szabó, Noémi Csákány-Papp, Marietta Görög, Tamara Madácsy, Árpád Varga, Aletta Kiss, Bálint Tél, Boldizsár Jójárt, Tim Crul, Krisztina Dudás and 9 more

Abstract read
In one paragraph

Article in JCI insight, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. CRAC channels as targets for immunotherapy.Current opinion in immunology · 2026
    Review
  3. Orai1 is required for CabioRxiv : the preprint server for biology · 2026
    Article
  4. Personalizing treatment of pancreatitis-associated chronic pain: the need for an integrated omics approach.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  5. Review
  6. Article
  7. Targeted therapeutics for pancreatitis.Frontiers in physiology · 2026
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Store-Operated CaContact (Thousand Oaks (Ventura County, Calif.))
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Viktória SzabóDepartment of Medicine.
Noémi Csákány-PappDepartment of Medicine.
Marietta GörögDepartment of Medicine.
Tamara MadácsyDepartment of Medicine.
Árpád VargaDepartment of Medicine.
Aletta KissDepartment of Medicine.
Bálint TélDepartment of Medicine.
Boldizsár JójártDepartment of Medicine.
Tim CrulDepartment of Medicine.
Krisztina DudásDepartment of Medicine.
Mária BagyánszkiDepartment of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics.
Nikolett BódiDepartment of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics.
Ferhan AyaydinHCEMM-USZ Functional Cell Biology and Immunology Advanced Core Facility, and.
Shyam JeeHCEMM-USZ Functional Cell Biology and Immunology Advanced Core Facility, and.
László TiszlaviczDepartment of Pathology, University of Szeged, Szeged, Hungary.
Kenneth A StaudermanCalciMedica Inc., La Jolla, California, USA.
Sudarshan HebbarCalciMedica Inc., La Jolla, California, USA.
Petra PallagiDepartment of Medicine.
József MaléthDepartment of Medicine.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with recurrent acute pancreatitis (RAP) are at significant risk of developing early chronic pancreatitis (CP), which progresses into irreversible, end-stage CP with severe symptoms. There is no specific therapy in RAP or in early CP that may hinder disease progression. The pathogenesis of CP is complex and involves interactions among multiple cell types, including pancreatic acinar, ductal, and stellate cells (PSC). Therefore, it is pivotal to identify common pathogenic pathways in these cells that could be targeted pharmacologically. The Orai1-mediated store-operated Ca2+ entry (SOCE) is a ubiquitous signaling mechanism that may become overactivated in pathological states resulting in intracellular Ca2+ overload. In this study, we used ex vivo and in vivo preclinical disease models to demonstrate that Orai1 inhibition prevents progression of RAP and early CP. The selective Orai1 inhibitor CM5480 restored the expression of SOCE-associated regulatory factor in acinar cells, prevented uncontrolled Ca2+ elevation, protected acinar and ductal functions, mitigated immune cell infiltration, and diminished PSC activation, proliferation, and migration. We suggest that the overactivation of Orai1 is a crucial pathogenetic event in the progression of early CP and that inhibition of Orai1 could prevent the development of end-stage CP.

Indexed as

CalciumPancreatitis, ChronicAcute DiseaseCalcium ChannelsHumansORAI1 ProteinCalciumCalcium ChannelsORAI1 ProteinCalcium channelsCalcium signalingCell BiologyFibrosisGastroenterology

Identifiers

PMID37227782
PMCPMC10371343

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.